The precision oncology company 4D Path has committed to partnering with the U.K.-based University of Leeds at least until 2027. The two entities are already collaborators, having worked together on three completed breast cancer clinical trials. In particular, researchers at the University of Leeds have used 4D Path’s Q-plasia OncoReader Breast software to analyze data from more…